Book Review: Cellular Replacement Therapy for Parkinson’s Disease—Where We Are Today?
- 1 October 2002
- journal article
- review article
- Published by SAGE Publications in The Neuroscientist
- Vol. 8 (5) , 457-488
- https://doi.org/10.1177/107385802237703
Abstract
The concept of replacing lost dopamine neurons in Parkinson’s disease using mesencephalic brain cells from fetal cadavers has been supported by over 20 years of research in animals and over a decade of clinical studies. The ambitious goal of these studies was no less than a molecular and cellular “cure” for Parkinson’s disease, other neurodegenerative diseases, and spinal cord injury. Much research has been done in rodents, and a few studies have been done in nonhuman primate models. Early uncontrolled clinical reports were enthusiastic, but the outcome of the first randomized, double blind, controlled study challenged the idea that dopamine replacement cells can cure Parkinson’s disease, although there were some significant positive findings. Were the earlier animal studies and clinical reports wrong? Should we give up on the goal? Some aspects of the trial design and implantation methods may have led to lack of effects and to some side effects such as dyskinesias. But a detailed review of clinical neural transplants published to date still suggests that neural transplantation variably reverses some aspects of Parkinson’s disease, although differing methods make exact comparisons difficult. While the randomized clinical studies have been in progress, new methods have shown promise for increasing transplant survival and distribution, reconstructing the circuits to provide dopamine to the appropriate targets and with normal regulation. Selected promising new strategies are reviewed that block apoptosis induced by tissue dissection, promote vascularization of grafts, reduce oxidant stress, provide key growth factors, and counteract adverse effects of increased age. New sources of replacement cells and stem cells may provide additional advantages for the future. Full recovery from parkinsonism appears not only to be possible, but a reliable cell replacement treatment may finally be near.Keywords
This publication has 293 references indexed in Scilit:
- Diminished Survival of Mesencephalic Dopamine Neurons Grafted into Aged Hosts Occurs during the Immediate Postgrafting IntervalExperimental Neurology, 2001
- Time Course of Apoptotic Cell Death within Mesencephalic Cell Suspension Grafts: Implications for Improving Grafted Dopamine Neuron SurvivalExperimental Neurology, 2000
- GDNF triggers fiber outgrowth of fetal ventral mesencephalic grafts from nigra to striatum in 6-OHDA-lesioned ratsCell and tissue research, 1996
- Cellular expression of GDNF mRNA suggests multiple functions inside and outside the nervous systemCell and tissue research, 1996
- N‐Acetylcysteine inhibits apoptosis and decreases viral particles in HIV‐chronically infected U937 cellsFEBS Letters, 1993
- Naturally Occurring Cell Death during Postnatal Development of the Substantia Nigra Pars Compacta of RatMolecular and Cellular Neuroscience, 1993
- Long distance directed axonal growth from human dopaminergic mesencephalic neuroblasts implanted along the nigrostriatal pathway in 6‐hydroxydopamine lesioned adult ratsJournal of Comparative Neurology, 1992
- Development of dopaminergic neurons in the human substantia nigraExperimental Neurology, 1991
- Development of intracerebral dopaminergic grafts: A combined immunohistochemical and autoradiographic study of its time course and environmental influencesJournal of Comparative Neurology, 1988
- Differential responsiveness to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in sub-regions of the primate substantia nigra and striatumLife Sciences, 1987